| A Study of LY3316531 in Healthy Participants (NCT03611608) | Eli Lilly and Company | 2018-08-30 |
| A Study of LY3209590 in Japanese Participants With Type 2 Diabetes (NCT03603704) | Eli Lilly and Company | 2018-08-17 |
| Study of LY3154207 in Healthy Participants (NCT03616795) | Eli Lilly and Company | 2018-08-09 |
| Study to Compare 2 Formulations of LY900014 in Healthy Participants (NCT03616977) | Eli Lilly and Company | 2018-08-03 |
| A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (NCT03616912) | Eli Lilly and Company | 2018-08-02 |
| A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II) (NCT03616964) | Eli Lilly and Company | 2018-08-02 |
| A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants (NCT05630287) | Eli Lilly and Company | 2018-08-01 |
| A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine (NCT03559257) | Eli Lilly and Company | 2018-07-31 |
| A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) (NCT03519945) | Eli Lilly and Company | 2018-07-18 |
| A Study of LY3322207 in Healthy Participants and in Participants With Hypertension (High Blood Pressure) (NCT03590860) | Eli Lilly and Company | 2018-07-13 |
| A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants (NCT05338476) | Eli Lilly and Company | 2018-07-12 |
| A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis (NCT03559270) | Eli Lilly and Company | 2018-06-27 |
| A Study of Lasmiditan in Healthy Japanese and Caucasian Participants (NCT03579940) | Eli Lilly and Company | 2018-06-27 |
| A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) (NCT03535194) | Eli Lilly and Company | 2018-06-26 |
| An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) (NCT03518086) | Eli Lilly and Company | 2018-06-18 |
| A Study of LY3314814 in Participants With Liver Impairment (NCT03499041) | Eli Lilly and Company | 2018-06-01 |
| A Study of Lanabecestat in Healthy Female Participants Taking Oral Contraceptive (NCT03506399) | Eli Lilly and Company | 2018-06-01 |
| A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants (NCT03545087) | Eli Lilly and Company | 2018-06-01 |
| A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants (NCT05468164) | Eli Lilly and Company | 2018-05-31 |
| A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable (NCT03428100) | Eli Lilly and Company | 2018-05-15 |
| A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants (NCT05338489) | Eli Lilly and Company | 2018-05-11 |
| A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease (NCT03518073) | Eli Lilly and Company | 2018-04-30 |
| A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis (NCT03482011) | Eli Lilly and Company | 2018-04-24 |
| A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer (NCT03414047) | Eli Lilly and Company | 2018-04-10 |
| A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes (NCT03495102) | Eli Lilly and Company | 2018-04-05 |
| A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function (NCT03482024) | Eli Lilly and Company | 2018-03-30 |
| A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis (NCT03334435) | Eli Lilly and Company | 2018-03-28 |
| A Study of LY900014 in Participants With Type 1 Diabetes Mellitus (NCT03465878) | Eli Lilly and Company | 2018-03-26 |
| A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants (NCT03459612) | Eli Lilly and Company | 2018-03-26 |
| A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus (NCT03338023) | Eli Lilly and Company | 2018-03-23 |
| Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (NCT03382912) | Eli Lilly and Company | 2018-03-22 |
| A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus (NCT03338010) | Eli Lilly and Company | 2018-03-22 |
| Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (NCT03382899) | Eli Lilly and Company | 2018-03-19 |
| A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus (NCT03449433) | Eli Lilly and Company | 2018-03-15 |
| A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine (NCT03432286) | Eli Lilly and Company | 2018-03-14 |
| A Study of LY3074828 in Healthy Participants (NCT03456713) | Eli Lilly and Company | 2018-03-06 |
| A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus (NCT03421379) | Eli Lilly and Company | 2018-02-21 |
| A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes (NCT03433677) | Eli Lilly and Company | 2018-02-21 |
| A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis (NCT03435081) | Eli Lilly and Company | 2018-02-20 |
| A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus (NCT03407118) | Eli Lilly and Company | 2018-02-17 |
| A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis (NCT03418493) | Eli Lilly and Company | 2018-01-30 |
| A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (NCT03443024) | Eli Lilly and Company | 2018-01-30 |
| A Study of Lasmiditan in Healthy Elderly Participants (NCT03406260) | Eli Lilly and Company | 2018-01-25 |
| A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants (NCT04194892) | Eli Lilly and Company | 2018-01-19 |
| A Study of LY3209590 in Participants With Type 2 Diabetes (NCT03367377) | Eli Lilly and Company | 2018-01-03 |
| A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps (NCT02623478) | Eli Lilly and Company | 2018-01-01 |
| A Study of a New Type of Insulin in Participants With Type 1 Diabetes on Insulin Injection Therapy (NCT02623452) | Eli Lilly and Company | 2018-01-01 |
| A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy (NCT02623465) | Eli Lilly and Company | 2018-01-01 |
| A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) (NCT03381547) | Eli Lilly and Company | 2017-12-18 |
| A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) (NCT03367403) | Eli Lilly and Company | 2017-12-18 |
| Assessment of Mealtime Bolus Insulin Behavior (NCT03368807) | Eli Lilly and Company | 2017-12-11 |
| A Study of Dulaglutide in Healthy Participants (NCT03363906) | Eli Lilly and Company | 2017-12-07 |
| A Study to Compare 2 Formulations of LY900014 in Healthy Participants (NCT03334448) | Eli Lilly and Company | 2017-12-04 |
| Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis (NCT03334422) | Eli Lilly and Company | 2017-11-27 |
| A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis (NCT03334396) | Eli Lilly and Company | 2017-11-23 |
| A Study of LY3375880 in Healthy Participants (NCT03343587) | Eli Lilly and Company | 2017-11-17 |
| A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (NCT03343613) | Eli Lilly and Company | 2017-11-17 |
| A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes (NCT03322631) | Eli Lilly and Company | 2017-11-15 |
| A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus (NCT03341299) | Eli Lilly and Company | 2017-11-13 |
| A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus (NCT03339453) | Eli Lilly and Company | 2017-11-10 |
| A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) (NCT03305809) | Eli Lilly and Company | 2017-11-09 |
| A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM) (NCT03367390) | Eli Lilly and Company | 2017-11-08 |
| A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes (NCT03315780) | Eli Lilly and Company | 2017-10-28 |
| A Study of Multiple Doses of LY3305677 in Healthy Participants (NCT03325387) | Eli Lilly and Company | 2017-10-27 |
| A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes (NCT03311724) | Eli Lilly and Company | 2017-10-19 |
| A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma (NCT03283696) | Eli Lilly and Company | 2017-10-18 |
| A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants (NCT03310411) | Eli Lilly and Company | 2017-10-17 |
| A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate (NCT03308669) | Eli Lilly and Company | 2017-10-16 |
| A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants (NCT03286751) | Eli Lilly and Company | 2017-10-13 |
| A Study of LY900014 in Participants With Type 2 Diabetes Mellitus (NCT03305822) | Eli Lilly and Company | 2017-10-11 |
| A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users (NCT03286218) | Eli Lilly and Company | 2017-09-15 |
| A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) (NCT03267732) | Eli Lilly and Company | 2017-09-05 |